| Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity A Casazza, D Laoui, M Wenes, S Rizzolio, N Bassani, M Mambretti, ... Cancer cell 24 (6), 695-709, 2013 | 664 | 2013 |
| MET is required for the recruitment of anti-tumoural neutrophils V Finisguerra, G Di Conza, M Di Matteo, J Serneels, S Costa, ... Nature 522 (7556), 349-353, 2015 | 479 | 2015 |
| Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment A Casazza, G Di Conza, M Wenes, V Finisguerra, S Deschoemaeker, ... Oncogene 33 (14), 1743-1754, 2014 | 292 | 2014 |
| miR-511-3p Modulates Genetic Programs of Tumor-Associated Macrophages ML Squadrito, F Pucci, L Magri, D Moi, GD Gilfillan, A Ranghetti, ... Cell Reports, 2012 | 234 | 2012 |
| Sema3E–Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice A Casazza, V Finisguerra, L Capparuccia, A Camperi, JM Swiercz, ... The Journal of clinical investigation 120 (8), 2684-2698, 2010 | 204 | 2010 |
| Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models A Casazza, X Fu, I Johansson, L Capparuccia, F Andersson, ... Arteriosclerosis, thrombosis, and vascular biology 31 (4), 741-749, 2011 | 148 | 2011 |
| Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility D Barberis, S Artigiani, A Casazza, S Corso, S Giordano, CA Love, ... The FASEB journal 18 (3), 592-594, 2004 | 138 | 2004 |
| p190 Rho-GTPase activating protein associates with plexins and it is required for semaphorin signalling D Barberis, A Casazza, R Sordella, S Corso, S Artigiani, J Settleman, ... Journal of cell science 118 (20), 4689-4700, 2005 | 133 | 2005 |
| The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment C Rolny, L Capparuccia, A Casazza, M Mazzone, A Vallario, A Cignetti, ... The Journal of experimental medicine 205 (5), 1155-1171, 2008 | 126 | 2008 |
| Tumour growth inhibition and anti‐metastatic activity of a mutated furin‐resistant Semaphorin 3E isoform A Casazza, B Kigel, F Maione, L Capparuccia, O Kessler, E Giraudo, ... EMBO molecular medicine, 2012 | 114 | 2012 |
| Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity Nature Communication 8 (14206), 2017 | 110 | 2017 |
| Cross-talk between vascular endothelial growth factor and semaphorin-3A pathway in the regulation of normal and malignant mesothelial cell proliferation A Catalano, P Caprari, S Rodilossi, P Betta, M Castellucci, A Casazza, ... Faseb Journal 18 (2), 358-60, 2004 | 100 | 2004 |
| Semaphorin signals in cell adhesion and cell migration: functional role and molecular mechanisms A Casazza, P Fazzari, L Tamagnone Semaphorins: Receptor and Intracellular Signaling Mechanisms, 90-108, 2007 | 88 | 2007 |
| Identification of a chronic non‐neurodegenerative microglia activation state in a mouse model of peroxisomal β‐oxidation deficiency S Verheijden, L Beckers, A Casazza, O Butovsky, M Mazzone, M Baes Glia 63 (9), 1606-1620, 2015 | 43 | 2015 |
| In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models J Cornillie, A Wozniak, P Pokreisz, A Casazza, L Vreys, J Wellens, ... Molecular Cancer Therapeutics 16 (8), 1566-1575, 2017 | 18 | 2017 |
| Altering the intratumoral localization of macrophages to inhibit cancer progression A Casazza, M Mazzone Oncoimmunology 3 (3), e27872, 2014 | 13 | 2014 |
| Sustained placental growth factor-2 treatment does not aggravate advanced atherosclerosis in ischemic cardiomyopathy M Wu, P Pokreisz, M Swinnen, E Caluwe, H Gillijns, N Vanden Driessche, ... Journal of Cardiovascular Translational Research 10 (4), 348-358, 2017 | 7 | 2017 |
| PhAc-ALGP-Dox, a novel anticancer prodrug with targeted activation and improved therapeutic index A Casazza, L Van Helleputte, B Van Renterghem, P Pokreisz, N De Geest, ... Molecular cancer therapeutics 21 (4), 568-581, 2022 | 5 | 2022 |
| Enhanced antitumor efficacy of PhAc-ALGP-Dox, an enzyme-activated doxorubicin prodrug, in a panel of THOP1-expressing patient-derived xenografts of soft tissue sarcoma B Van Renterghem, A Wozniak, L Tarantola, A Casazza, J Wellens, ... Biomedicines 10 (4), 862, 2022 | 1 | 2022 |
| Sema3E–Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice A Casazza, V Finisguerra, L Capparuccia, A Camperi, JM Swiercz, ... The Journal of Clinical Investigation 121 (7), 2945-2945, 2011 | 1 | 2011 |
Massimiliano MazzoneGroup Leader, Vesalius Research CenterEmail verificata su vib-kuleuven.be
